Park Avenue Securities LLC Buys 75 Shares of Repligen Co. (NASDAQ:RGEN)

Park Avenue Securities LLC boosted its stake in Repligen Co. (NASDAQ:RGEN – Get Rating) by 2.5% in the first quarter, HoldingsChannel reports. The firm owned 3,118 shares of the biotechnology company’s stock after acquiring an additional 75 shares during the period. Park Avenue Securities LLC’s holdings in Repligen were worth $586,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RGEN. Allspring Global Investments Holdings LLC bought a new stake in Repligen in the fourth quarter valued at about $218,643,000. Millennium Management LLC increased its holdings in Repligen by 186.2% in the fourth quarter. Millennium Management LLC now owns 309,482 shares of the biotechnology company’s stock valued at $81,963,000 after purchasing an additional 201,342 shares during the last quarter. Impax Asset Management Group plc increased its holdings in Repligen by 31.6% in the fourth quarter. Impax Asset Management Group plc now owns 813,012 shares of the biotechnology company’s stock valued at $214,295,000 after purchasing an additional 195,300 shares during the last quarter. Conestoga Capital Advisors LLC increased its holdings in Repligen by 18.2% in the first quarter. Conestoga Capital Advisors LLC now owns 772,719 shares of the biotechnology company’s stock valued at $145,341,000 after purchasing an additional 118,818 shares during the last quarter. Finally, First Trust Advisors LP increased its holdings in shares of Repligen by 174.3% in the fourth quarter. First Trust Advisors LP now owns 135,124 shares of the biotechnology company’s stock worth $35,786,000 after acquiring an additional 85,857 shares in the last quarter. Institutional investors own 86.82% of the company’s stock.

Insider Activity at Repligen

In related news, Director Karen A. Dawes sold 14,715 shares of the stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total transaction of $2,214,754.65. Following the completion of the transaction, the director now directly owns 76,532 shares of the company’s stock, valued at $11,518,831.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Karen A. Dawes sold 14,715 shares of the stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $150.51, for a total transaction of $2,214,754.65. Following the completion of the transaction, the director now directly owns 76,532 shares of the company’s stock, valued at $11,518,831.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Anthony Hunt sold 24,802 shares of the stock in a transaction that occurred on Thursday, July 21st. The shares were sold at an average price of $200.00, for a total value of $4,960,400.00. Following the transaction, the chief executive officer now directly owns 194,667 shares of the company’s stock, valued at $38,933,400. The disclosure for this sale can be found here. Insiders own 1.10% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RGEN. UBS Group began coverage on Repligen in a report on Wednesday. They issued a “buy” rating and a $213.00 price target for the company. StockNews.com began coverage on Repligen in a report on Thursday, March 31st. They issued a “hold” rating for the company. Finally, Craig Hallum lowered their price target on Repligen from $286.00 to $274.00 in a report on Thursday, April 28th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $288.86.

Repligen Price Performance

RGEN stock opened at $201.74 on Friday. The stock has a market capitalization of $10.98 billion, a P/E ratio of 79.74 and a beta of 0.95. The business has a 50-day moving average of $162.03 and a 200-day moving average of $172.56. Repligen Co. has a fifty-two week low of $137.21 and a fifty-two week high of $327.32.

Repligen (NASDAQ:RGEN – Get Rating) last posted its quarterly earnings data on Wednesday, April 27th. The biotechnology company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.20. The company had revenue of $206.40 million during the quarter, compared to analysts’ expectations of $185.48 million. Repligen had a return on equity of 11.13% and a net margin of 19.86%. Repligen’s revenue for the quarter was up 44.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.68 earnings per share. Equities analysts expect that Repligen Co. will post 3.1 EPS for the current year.

Repligen Profile

(Get Rating)

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.